GEO accession GSE302554 is currently private and is scheduled to be released on Jul 31, 2025.
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1291184 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Gliomas are the most common type of primary malignant adult brain tumor. They appear to originate from neuroglial stem or progenitor cells, and are therapeutically challenging due to an invasive growth pattern and the absence of effective therapies. We have analyzed cellular, molecular and proteomic features and defined the therapeutic response profiles of four IDH1-wildtype glioma stem cell (GSC) cultures. All four GSC cultures were established from Grade IV glioblastoma (GBM) surgical resection tissue, can be continuously propagated and are highly enriched for stem/tumor repopulating cells. Integrated genomic and proteomic analysis of all four cultures was performed, together with use of a dual molecular bar-coding strategy to assess GSC population heterogeneity and the response to ionizing radiation. These well-characterized, bar-coded GSC cultures provide an experimentally tractable resource for investigating glioma biology, and to use to identify new and potentially more effective GBM therapies and treatment regimens.
2026-02-02 | PXD035886 | Pride
Project description:Changes in Histone H3 acetylation in panobinostat-treated IDH-wildtype and IDH-mutant glioma cultures
| PRJNA1331758 | ENA
Project description:Glioblastoma stem cell cultures (GSCs) are initiated from glioblastoma (GBM) surgical resection tissue, and can capture and propagate key GBM molecular and cellular features. We have deeply characterized four IDH-wildtype GSCs from unrelated adults as cellular models of a majority of adult primary GBMs. These GSC cultures could be continuously propagated in defined, serum-free media and 5% oxygen without requiring specialized growth substrates. They had well-defined genomic and mtDNA variants and gene and protein expression profiles. All four had highly reproducible dose response curves to the GBM standard-of-care therapies of ionizing radiation (IR) and temozolomide (TMZ). Expressed lentiviral barcodes, mtDNA variants and single cell gene expression profiling were used to define cellular heterogeneity, and to track individual cell trajectories and their gene expression programs over 40 days after IR treatment. These well-characterized GSC cultures can support many high throughput in vitro assay formats, as well as xenograft, organoid and other GBM disease modeling approaches. Their use should help to better understand GBM biology, and to identify new and more effective GBM therapies and treatment regimens.
2026-01-28 | GSE302554 | GEO
Project description:Glioblastoma stem cell cultures (GSCs) are initiated from glioblastoma (GBM) surgical resection tissue, and can capture and propagate key GBM molecular and cellular features. We have deeply characterized four IDH-wildtype GSCs from unrelated adults as cellular models of a majority of adult primary GBMs. These GSC cultures could be continuously propagated in defined, serum-free media and 5% oxygen without requiring specialized growth substrates. They had well-defined genomic and mtDNA variants and gene and protein expression profiles. All four had highly reproducible dose response curves to the GBM standard-of-care therapies of ionizing radiation (IR) and temozolomide (TMZ). Expressed lentiviral barcodes, mtDNA variants and single cell gene expression profiling were used to define cellular heterogeneity, and to track individual cell trajectories and their gene expression programs over 40 days after IR treatment. These well-characterized GSC cultures can support many high throughput in vitro assay formats, as well as xenograft, organoid and other GBM disease modeling approaches. Their use should help to better understand GBM biology, and to identify new and more effective GBM therapies and treatment regimens.
2026-01-28 | GSE303069 | GEO
Project description:Glioblastoma stem cell (GSC) cultures are initiated from glioblastoma (GBM) surgical resection tissue. They can capture and propagate key GBM primary tumor molecular and cellular features. We have deeply characterized four IDH-expressing (IDH+ or ‘wildtype’) GSC cultures from unrelated adults to serve as cellular models for the majority of adult primary GBM. We demonstrate that GSC cultures can be continuously propagated in defined, serum-free media and 5% oxygen without requiring specialized growth substrates; have well-defined genomic and mtDNA variants and gene/protein expression profiles; and highly reproducible dose-survival curves when treated with the GBM standard-of-care therapies of ionizing radiation (IR) and temozolomide (TMZ). We also illustrate how expressed lentiviral barcodes, mtDNA variants and single cell gene expression profiling can be used to define and track cellular heterogeneity over 40 days after IR treatment. These well-characterized IDH+ GSC cultures can support many high throughput in vitro assay formats, including xenograft, organoid and other GBM disease modeling protocols. They should prove a useful resource to better understand GBM biology, and to identify new and more effective GBM therapies and treatment regimens.
2026-01-28 | GSE303662 | GEO
Project description:RNA-sequencing for myeloid inflammation-related genes was conducted on primary tumor samples from patients with IDH-wildtype glioblastoma (GBM) and grade 4 IDH-mutant astrocytoma (G4IMA). In addition, the IDH-wildtype murine glioma cell line GL261 and a strain of IDH-mutant GL261 were also sequenced using the murine counterpart of the RNA-sequencing myeloid innate immunity panel.
2024-05-29 | GSE268118 | GEO
Project description:Oligoastrocytoma (OA) was formerly defined as a mixed glioma exhibiting histological features of both astrocytoma and oligodendroglioma. However, OA has been shown to be attributable to either glioma-type based on its molecular characteristics and was excluded from the glioma classification with the introduction of the integrated diagnosis. Nevertheless, some cases showing genetic features of both oligodendroglioma and astrocytoma have been reported since the integrated diagnosis era, and whether OA exists as a glioma-type remains controversial. All previously reported cases were mixed gliomas with and without 1p/19q-codeletion in the lineage of isocitrate dehydrogenase (IDH) mutant gliomas. Herein, we described a 33-year-old man with a progressive headache. Magnetic resonance imaging showed a large left frontal lobe tumor composed of a cystic component with contrast-enhancing walls and a non-contrast-enhancing solid component. The patient underwent a gross total removal of the tumor. Histologically, the cystic and solid components showed oligodendroglioma and astrocytoma morphology, respectively. Immunohistochemically, IDH1-R132H staining was positive in the cystic component and negative in the solid component. Sanger sequencing confirmed the IDH1-R132H mutation and the C228T mutation in the telomerase reverse transcriptase promoter (TERTp) region in the cystic component, while both IDH1/2 and TERTp were wildtype in the solid component. Fluorescence in situ hybridization revealed 1p/19q-codeletion in both areas. The integrated diagnosis led to the diagnosis of oligoastrocytoma consisting of IDH-mutant 1p/19q-codeleted oligodendroglioma and IDH-wildtype astrocytoma. Furthermore, deoxyribonucleic acid (DNA) extracted separately from each area of formalin-fixed paraffin-embedded specimen revealed a distinct methylation profile. On the other hand, the global DNA copy-number analysis derived from the microarray data showed similar copy-number profiles including 1p/19q-codeletion for both sites. This is the first report of a dual-genotype oligoastrocytoma with IDH-mutant 1p/19q-codeleted oligodendroglioma and IDH-wildtype astrocytoma. This extremely rare case provides profound insight into the process of acquiring genetic abnormalities in the development of glioma.
2025-10-31 | GSE280730 | GEO
Project description:This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
| 92735 | ecrin-mdr-crc
Project description:IDH1/2 mutations (IDHmut) increase methylation of DNA and histones in gliomas. IDHmut inhibitors are effective against low-grade IDHmut gliomas, but new strategies against high grade IDHmut gliomas are needed. Although histone deacetylase inhibitors (HDACi) are ineffective against IDHwt glioblastoma (GBM), their potential in IDHmut gliomas has not been extensively studied. We previously established that IDHmut gliomas are more sensitive to HDACi than IDHwt GBM. Here we show that IDHmut is associated with greater sensitivity to HDACi in glioma. While HDACi induced more histone acetylation and gene regulation in IDHmut glioma than in IDHwt GBM, ChIP-Seq studies show such acetylation was mostly within gene deserts, whereas IDHmut glioma promoters paradoxically lost histone acetylation.
2025-09-19 | GSE308631 | GEO
Project description:Genome wide DNA methylation profiling of IDH-wildtype, H3-wildtype AYA glioblastomas
2022-02-12 | GSE196490 | GEO